ライフサイエンスコーパス: strategy to overcome

1 w potential target molecules for therapeutic strategies to overcome 5-FU resistance.

2 monstrate that targeting Rac1 is a potential strategy to overcome acquired chemoresistance in breast

3 hibitors has emerged as a potential clinical strategy to overcome acquired resistance to BRAF and MEK

4 n-RAF activities is an effective therapeutic strategy to overcome acquired-resistance to vemurafenib.

5 no acids with Cip was also investigated as a strategy to overcome anti-microbial resistance in these

6 a rational base for the development of novel strategies to overcome antiangiogenic resistance in the

7 l show whether necroptosis is truly a better strategy to overcome apoptosis resistance and provide th

8 nction ARVs, and furthermore, they provide a strategy to overcome ARV function in the clinic.

9 field should embrace telehealth and develop strategies to overcome associated challenges.

10 programs at 21 medical schools, the various strategies to overcome barriers in training physicians i

11 duce health inequities globally must include strategies to overcome barriers to care, especially for

12 ach highlights the potential of mobilization strategies to overcome barriers to successful engraftmen

13 y identification of barriers to tool use and strategies to overcome barriers.

14 y have led to the development of therapeutic strategies to overcome castration resistance.

15 alytic CO(2) reduction is crucial to develop strategies to overcome catalytic bottlenecks.

16 at addressing this shortfall by identifying strategies to overcome challenges, developing the tools

17 cquired chemoresistance to TMZ and potential strategies to overcome chemoresistance are, therefore, c

18 lowing the development of improved treatment strategies to overcome chemoresistance.

19 herapeutic efficacy, thereby providing a new strategy to overcome chemoresistance and to improve the

20 t targeting HMGB3 is a potential therapeutic strategy to overcome chemoresistance in ovarian cancer.

21 the ERCC1-XPF complex as a novel therapeutic strategy to overcome chemoresistance.

22 d to these phenotypes, but optimal treatment strategies to overcome chemotherapeutic resistance and e

23 unction, therefore, presents a promising new strategy to overcome chemotherapy resistance in breast c

24 P11B expression could serve as a therapeutic strategy to overcome cisplatin resistance.

25 Strategies to overcome clinical inertia must focus on me

26 livery of T-CPR instructions, and identifies strategies to overcome common implementation barriers to

27 pathways downstream of AR could be a viable strategy to overcome CRPC.

28 Federated Learning presents a promising strategy to overcome current obstacles in developing AI

29 targeting MYC may be a promising therapeutic strategy to overcome de novo BET bromodomain inhibitor r

30 nza, and suggest that additional therapeutic strategies to overcome defective antibacterial immunity

31 a prophylactic, potent, and safe therapeutic strategy to overcome DFP toxicity.

32 A strategy to overcome disease-causing nonsense mutations

33 Therefore, new combination strategies to overcome drug resistance in patients with

34 tacle for long-term remission, and effective strategies to overcome drug resistance would have signif

35 In this study, we have provided four strategies to overcome drug resistance.

36 ettes promise to yield novel, more-effective strategies to overcome drug resistance.

37 itors, which also can be used to develop new strategies to overcome drug-resistant mRCC.

38 Such approach could be seen as a promising strategy to overcome drug resistance and enhance the eff

39 nd a TYR-catalyzed in-situ activated prodrug strategy to overcome drug resistance for melanoma therap

40 of autoreactive B cells and represents a new strategy to overcome drug resistance in human ALL.

41 B-cell selection represents a promising new strategy to overcome drug resistance in human ALL.

42 al inhibition of GLI1, revealing a potential strategy to overcome drug resistance in some patients.

43 andidate target to develop novel therapeutic strategy to overcome drug resistance.

44 c mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mutations that

45 Strategies to overcome EGFR T790M-mediated drug resistan

46 Here, we investigated a novel strategy to overcome EGFR TKI resistance through targeti

47 in breast cancer drug development, including strategies to overcome endocrine and human epidermal gro

48 st antidonor T cells and suggest a practical strategy to overcome engraftment barriers in primed indi

49 Therefore, strategies to overcome epigenetic modifications underlyi

50 and underscore targeting AATF as a potential strategy to overcome GB resistance to chemoradiotherapy.

51 nsure that the goal of the National HIV/AIDS Strategy to overcome health disparities becomes a realit

52 e possibility that bacteria may have evolved strategies to overcome host cell apoptosis was explored

53 Bacteriophages have evolved diverse strategies to overcome host defence mechanisms and to re

54 t pathogens utilize many universal offensive strategies to overcome host defenses, irrespective of th

55 different clones may have adopted different strategies to overcome host responses and cause severe p

56 indicate that influenza virus has evolved a strategy to overcome host innate immunity by downregulat

57 t CLL cells may provide novel drug treatment strategies to overcome ibrutinib resistance mediated by

58 ether these data provide a novel therapeutic strategy to overcome imatinib mesylate resistance, espec

59 ntial targets for development of therapeutic strategies to overcome immune evasion.

60 ells, to solid tumors requires combinatorial strategies to overcome immune suppression associated wit

61 s with a mesenchymal phenotype and suggest a strategy to overcome immune evasion through induction of

62 A promising strategy to overcome immune rejection is to genetically

63 tion may represent an attractive therapeutic strategy to overcome immune tolerance in breast cancer.

64 on of cancer cells and may provide a general strategy to overcome immunotherapy resistance.

65 Nano-TDDS-based TAM modulation, highlighting strategies to overcome in vivo delivery barriers associa

66 eted CAR T cells and explored cell-intrinsic strategies to overcome inhibition of CAR T cells.

67 e present a non-competitive active transport strategy to overcome intestinal barriers in the form of

68 have shown that viruses have evolved a novel strategy to overcome intestinal mucinous barriers agains

69 roposes innate immunoreceptor targeting as a strategy to overcome intrinsic T cell resistance of IFN-

70 However, bacteria have evolved strategies to overcome iron starvation, for example, by

71 r this translational discrepancy and suggest strategies to overcome it with the next generation of PA

72 cope with disgust and use empathy as a main strategy to overcome it.

73 nst viruses, and many viruses have developed strategies to overcome its antiviral effects.

74 r, highlighting DCAF1-PROTACS as a promising strategy to overcome ligase mediated resistance in clini

75 ptor-mediated transcytosis offer a promising strategy to overcome limited blood-brain barrier permeab

76 protocols to silence immune checkpoints as a strategy to overcome locally active immune escape pathwa

77 ial for the clinical use of this therapeutic strategy to overcome MDR.

78 A recently proposed strategy to overcome multidrug resistance (MDR) in cance

79 ed small molecule combinations are potential strategies to overcome mutation-mediated resistance.

80 reports and demonstrates the first effective strategy to overcome NOB adaptation through alternating

81 Potential new strategies to overcome off-target nanomaterial accumulat

82 Here, we report the development of a strategy to overcome one of these barriers, phagolysosom

83 resistance to develop effective therapeutic strategies to overcome or prevent drug resistance.

84 subsequent treatment approaches and suggest strategies to overcome or prevent osimertinib resistance

85 sible EGFR inhibitors and reveal alternative strategies to overcome or prevent the development of res

86 Here, we explored strategies to overcome original antigenic sin responses

87 ssivation using NSE modifiers is a promising strategy to overcome outstanding issues impeding further

88 ting EMT and provide a rationale for a novel strategy to overcome oxaliplatin resistance in CRC.

89 ults provide valuable insights and potential strategies to overcome P-gp efflux, contributing to the

90 n these S-phase events, which may reveal new strategies to overcome PARP inhibitor resistance.

91 /beta-catenin pathway represents a potential strategy to overcome PARPi resistance.

92 al DNA complexes, and viruses will require a strategy to overcome particle binding and clearance by c

93 opulation through vaccination is a promising strategy to overcome pathogen epitope variability and to

94 es and outcomes researchers could serve as a strategy to overcome persisting gaps in cardiovascular q

95 Additionally, we explore potential strategies to overcome PI resistance.

96 is study, we define a targeted combinatorial strategy to overcome PLX4032/vemurafenib resistance in m

97 g SIRT1 represents an attractive therapeutic strategy to overcome primary resistance in defined subse

98 Novel therapeutic strategies to overcome proteasome inhibitor resistance a

99 gives credence to proposed dual-insecticide strategies to overcome pyrethroid resistance.

100 fore, essential to develop novel therapeutic strategies to overcome radioresistance and improve radio

101 To investigate therapeutic strategies to overcome resistance to anastrozole treatme

102 his JOCSynopsis, we summarize small molecule strategies to overcome resistance to beta-lactam antibio

103 anoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherap

104 t cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are u

105 ications related to the development of novel strategies to overcome resistance to tolerance.

106 elop better diagnostic tools and therapeutic strategies to overcome resistance.

107 nce EGFR mutations and evaluates therapeutic strategies to overcome resistance.

108 the recurrence mechanisms and development of strategies to overcome resistance.

109 on therapy, and prophylaxis were explored as strategies to overcome resistance.

110 antimicrobial therapies may be an important strategy to overcome resistance and broaden the spectrum

111 Importantly, it has become an indispensable strategy to overcome resistance in antibiotics, antimicr

112 stant OSCC cells, which could be a promising strategy to overcome resistance to anti-EGFR therapy.

113 pathways simultaneously may be an attractive strategy to overcome resistance to antiangiogenesis ther

114 e use of antiangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis ther

115 Therefore, a combination strategy to overcome resistance to EGFR mono-targeted th

116 transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inh

117 broad range of tumor cell lines to provide a strategy to overcome resistance to kinase inhibitor ther

118 F, thereby revealing a potential therapeutic strategy to overcome resistance to RAF inhibition in a s

119 ous lung tumors, thus providing an effective strategy to overcome resistance.

120 M2 inhibitor Nutlin-3A, which may serve as a strategy to overcome resistance.

121 and Aurora kinase is a rational therapeutic strategy to overcome resistance.

122 ption of CXCR7 signaling may be an effective strategy to overcome resistance.

123 or their upstream regulators is a promising strategy to overcome rituximab resistance.

124 hibition of the PI3K/Akt/mTOR pathway is one strategy to overcome SCLC resistance mediated by ECM.

125 A strategy to overcome scope limitation with respect to un

126 These findings provide a strategy to overcome several key limitations of CED that

127 h and economic value; however, complementary strategies to overcome social and structural barriers to

128 nct to iDA cell therapy, it presents a novel strategy to overcome some current caveats of cell replac

129 n of this pathway may represent an efficient strategy to overcome stromal-mediated chemotherapy refra

130 Strategies to overcome such challenges including viral r

131 imiting bnAb production to be elucidated and strategies to overcome such limitations to be evaluated.

132 Strategies to overcome such resistance are currently und

133 TNFalpha-induced apoptosis and corresponding strategies to overcome such resistance.

134 istance to endocrine therapies and potential strategies to overcome such resistance.

135 and autoimmunity and for the development of strategies to overcome T cell tolerance in situations su

136 that targeting TGFbeta might be a promising strategy to overcome T cell exclusion and improve clinic

137 iming and the effector phases and provides a strategy to overcome T(reg) cell-mediated suppression in

138 cond-generation EGFR TKI may be an effective strategy to overcome T790M-mediated drug resistance.

139 level of CCNE2 and that it could be a novel strategy to overcome TAM resistance in breast cancer pat

140 SynthEx utilizes a "synthetic-normal" strategy to overcome technical and financial issues.

141 s of compounds conferring cryotolerance, and strategies to overcome temperature-dependent barriers to

142 e in this regard has been the development of strategies to overcome the "crystallization problem", wh

143 Strategies to overcome the apparent irreversible hair ce

144 l types and approaches, and outline numerous strategies to overcome the associated obstacles.

145 onventional concepts of drug delivery, novel strategies to overcome the BBB can be developed.

146 at AOM consortia use specialized biochemical strategies to overcome the challenges of metal availabil

147 Limitations and strategies to overcome the challenges of paper biosensor

148 ng a critical reconsideration of engineering strategies to overcome the coercivity limits.

149 tries of siRNA formulations are enabling new strategies to overcome the core obstacles to delivery wh

150 I also discuss viral strategies to overcome the deleterious effects of cell d

151 Viruses have developed distinct strategies to overcome the host defense system.

152 nal tract, noroviruses have developed unique strategies to overcome the host defense system.

153 nvironment and discuss combination treatment strategies to overcome the limitations of immunologic mo

154 cluster biosynthetic pathway and suggest new strategies to overcome the loss of cellular FXN that may

155 ew toward how such information could lead to strategies to overcome the lower immunogenicity of vacci

156 ls, ICU directors, and ICU staff must devise strategies to overcome the modifiable determinants of ad

157 ansgenic mouse lung tumor models to evaluate strategies to overcome the most common EGFR TKI resistan

158 iciencies have led to a plethora of creative strategies to overcome the physical, chemical, and biolo

159 We anticipate that CyG will provide new strategies to overcome the pitfall of present day albumi

160 ience will require devising and implementing strategies to overcome the political, administrative, fi

161 learn from the sector in general and discuss strategies to overcome the present limitations.

162 all partial grafts, which mandates effective strategies to overcome the problems regarding insufficie

163 for gene therapy with viral vectors, unless strategies to overcome the rapid in vivo elimination of

164 Strategies to overcome the restoration of BCR-ABL signal

165 d males of many species to develop different strategies to overcome the sperm of competing males.

166 y have led to the development of therapeutic strategies to overcome the state of 'castration resistan

167 New strategies to overcome the thymic atrophy of aging are n

168 content and codon usage, and suggest simple strategies to overcome the transgene expression problem

169 herapy and nanomedicine, offering innovative strategies to overcome the tumor microenvironment (TME)

170 Pathogens have evolved different strategies to overcome the various barriers that they en

171 Stat3-targeted therapy is a new therapeutic strategy to overcome the acquired resistance to vemurafe

172 duce a supramolecular design as an effective strategy to overcome the canonical tradeoff between mech

173 ion of this pathway might represent a useful strategy to overcome the cell-inherent resistance to can

174 Drug combinations are a promising strategy to overcome the compensatory mechanisms and unw

175 e-amorphous hybrid structure is an effective strategy to overcome the conflict between the strength a

176 that particle size reduction is a pragmatic strategy to overcome the current limitation of mannitol

177 LNP-mediated delivery of uniSTING-mRNA as a strategy to overcome the current STING therapeutic barri

178 Finally, our results call for a strategy to overcome the financial and technical barrier

179 esents a novel single-agent immunomodulatory strategy to overcome the immune responses against transg

180 lated OPN represents a potential therapeutic strategy to overcome the inherent limitation of cytotoxi

181 A key programming strategy to overcome the lack of a simple overall parent

182 eted photosensitizer and red light) may be a strategy to overcome the limitations inherent in photody

183 proach may represent a potential therapeutic strategy to overcome the limitations of anti-VEGFR monot

184 ethylation and suggest the first alternative strategy to overcome the limitations of currently approv

185 hermore, we develop a slow sustained-release strategy to overcome the limited dispersibility of prote

186 ogenic expression of antigens is a promising strategy to overcome the limited long-term efficacy of a

187 re plans for identifying a commercialization strategy to overcome the major financial barriers that e

188 This nano-antibiotic represents a strategy to overcome the mucus barrier, increase local d

189 One strategy to overcome the obstacle of polymorphism is to

190 In this report, we used an shRNA-depletion strategy to overcome the oogenesis block.

191 Thus, ATR inhibition is a unique strategy to overcome the PARPi resistance of BRCA-defici

192 novo drug development - has been a promising strategy to overcome the paucity of treatments available

193 Cellular immunotherapy may provide a strategy to overcome the poor prognosis of metastatic an

194 ity of a multiple-site interaction, may be a strategy to overcome the problems for drug design associ

195 ic structure description of Cu(Z) provides a strategy to overcome the reaction barrier of N(2)O reduc

196 A novel strategy to overcome the resistance is to target the apo

197 A widely used chemical genetic strategy to overcome the specificity challenge exploits

198 ct serotypes may be an effective and general strategy to overcome the suppressive effects of pre-exis

199 ake solid tumors difficult to treat, as well strategies to overcome them and enhance drug penetration

200 rugiperda (Sf9) insect cell line and devised strategies to overcome them by overexpression of the enz

201 systems, primary physiological barriers and strategies to overcome them, and advances in preclinical

202 defects been elucidated, but two successful strategies to overcome them, namely adoptive immunothera

203 (each 1 mg/kg/h), suggesting a need for new strategies to overcome them.

204 diovascular disease and to discuss potential strategies to overcome them.

205 on revealed mechanisms of escape and enabled strategies to overcome them.

206 important causes of GVL failure and suggest strategies to overcome them.

207 thodically review these barriers and suggest strategies to overcome them.

208 the study of neurological disease and offer strategies to overcome them.

209 ing such an approach in a wider context, and strategies to overcome them.

210 ectrometry metabolomics datasets and suggest strategies to overcome them.

211 hat hinder tissue-specific drug delivery and strategies to overcome them.

212 m and highlight key limitations and possible strategies to overcome them.

213 ecific to antiangiogenic therapy and develop strategies to overcome them.

214 (each 1 mg/kg/h), suggesting a need for new strategies to overcome them.-Carter, J.

215 hibiting purine synthesis may be a promising strategy to overcome therapy resistance in this genomica

216 Strategies to overcome these barriers are as follows: in

217 Strategies to overcome these barriers include new small

218 mit realization of this vision, and possible strategies to overcome these barriers that can improve c

219 New strategies to overcome these barriers will be needed if

220 Strategies to overcome these challenges include drug del

221 Next-generation strategies to overcome these challenges, focusing on tar

222 gating the genetic basis of PAD and possible strategies to overcome these challenges; and (3) discuss

223 ation and spread, but viruses have developed strategies to overcome these defenses.

224 Strategies to overcome these hurdles are also reviewed,

225 Unfortunately, clinical strategies to overcome these lag far behind.

226 of ART-suppressed HIV-1 infection, we tested strategies to overcome these limitations and challenges.

227 Strategies to overcome these limitations are being pursu

228 After exploring several strategies to overcome these limitations, we show that e

229 We also provide an overview of potential strategies to overcome these obstacles in an effort to m

230 or engineered phages could provide effective strategies to overcome these obstacles.

231 ences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatme

232 is study, we demonstrate genetic engineering strategies to overcome these shortcomings by integrating

233 made, often resulting in low "hit rates." A strategy to overcome these approximations is to rescore

234 n of multiple epitopes was investigated as a strategy to overcome these barriers.

235 Here we describe a strategy to overcome these challenges, CISMR (CRISPR-med

236 discuss the potential of targeting HIFs as a strategy to overcome these instances of AA therapy resis

237 A feasible strategy to overcome these issues is migrating to pH-neu

238 Here we report a general strategy to overcome these limitations and achieve solut

239 notransplantation of porcine islets may be a strategy to overcome these supply problems.

240 Strategies to overcome this antigen-driven, cell-intrins

241 epitope variants have both been proposed as strategies to overcome this challenge.

242 e to drug resistance, as well as therapeutic strategies to overcome this clinically.

243 ustrial laboratories have explored different strategies to overcome this hurdle over the past two dec

244 designing the most appropriate and effective strategies to overcome this important and frequently und

245 e goal of guiding development of therapeutic strategies to overcome this limitation.

246 uated the interest of selective gene therapy strategies to overcome this limitation.

247 ms will play a significant role in informing strategies to overcome this meaningful limitation.

248 esistance and provides potential therapeutic strategies to overcome this mechanism of resistance.

249 ies that necessitates the development of new strategies to overcome this problem.

250 Strategies to overcome this resistance will be discussed

251 croenvironment allows for rational design of strategies to overcome this tolerance.

252 A viable strategy to overcome this accumulation is to replace con

253 One strategy to overcome this barrier is to use latency-reve

254 As a strategy to overcome this barrier, the use of stealth co

255 We have devised a pooled adapter strategy to overcome this bias, and validated the method

256 Recently, we demonstrated a general strategy to overcome this challenge by incorporating a b

257 A potential strategy to overcome this challenge is to target common

258 One recent strategy to overcome this challenge relies on protein-ba

259 -deazaxanthine (c7X) has been suggested as a strategy to overcome this effect.

260 Here we demonstrate a strategy to overcome this hurdle by avoiding the gaseous

261 This work proposes a data processing strategy to overcome this instrumental limitation and in

262 Here we report a general strategy to overcome this issue: "locking" the degradabi

263 with both an opportunity to understand and a strategy to overcome this leading cause of human morbidi

264 Dipolar excitons provide an attractive strategy to overcome this limitation but are often hinde

265 'Therapeutic cloning' is a strategy to overcome this limitation by generating nucle

266 ose and demonstrate a microstructural design strategy to overcome this limitation by matching the mic

267 e, we introduce a hierarchical self-assembly strategy to overcome this limitation by programming supr

268 One strategy to overcome this limitation is to target novel

269 One strategy to overcome this limitation is to use tetrahedr

270 One strategy to overcome this obstacle is to remove the meth

271 Here we test a unique signaling-based strategy to overcome this obstacle.

272 One strategy to overcome this problem is to use systems that

273 tors used by pathogens represents a powerful strategy to overcome this problem, because extensive alt

274 Here we present a strategy to overcome this problem, employing a Gal4-indu

275 al Ontologies (OBO) consortium is pursuing a strategy to overcome this problem.

276 One strategy to overcome this resistance is to inhibit other

277 ce to ABT-737, these results suggest a novel strategy to overcome this resistance.

278 tongue, and tracing seems to be an effective strategy to overcome this.

279 linical practice and presents implementation strategies to overcome those barriers.

280 nfirm 20S proteasome inhibitors as promising strategy to overcome TKI resistance in GIST, while highl

281 Thus, we have tested a potential strategy to overcome TM cell-driven rejection by targeti

282 g PTM-driven networks as a novel therapeutic strategy to overcome TMZ resistance and improve treatmen

283 finity/T-cell functional avidity, and pursue strategies to overcome tolerance and immunosuppression.

284 Stat3 inhibition may represent a therapeutic strategy to overcome tolerance to tumor antigens and eli

285 at targeting HOTAIR function may represent a strategy to overcome TRAIL resistance in pancreatic canc

286 poptosis, suggesting a potential therapeutic strategy to overcome TRAIL resistance.

287 may evolve developmentally associated escape strategies to overcome transcriptional gene silencing in

288 fficacy, thus constituting a novel candidate strategy to overcome trastuzumab resistance and improve

289 t blocking this loop may provide alternative strategy to overcome trastuzumab resistance.

290 g the potential clinical application of this strategy to overcome trastuzumab resistance.

291 tive breast cancers, potentially useful as a strategy to overcome trastuzumab resistance.

292 One of the promising strategies to overcome tumor multidrug resistance (MDR)

293 mune landscape offers insights into possible strategies to overcome tumor-supporting TME properties a

294 ecifically in tumor cells, and provide a new strategy to overcome tumor chemoresistance.

295 nd targeting SHP2 may serve as a therapeutic strategy to overcome tumor resistance to osimertinib.

296 Drug-based strategies to overcome tumour resistance to radiotherapy

297 mplications as they point to a potential new strategy to overcome VEGF blockade resistance; however,

298 These data suggest strategies to overcome VP35 inhibition of DC function.

299 ing with mRNA vaccines has been an effective strategy to overcome waning immunity and neutralization

300 sis of xenograft rejection and in developing strategies to overcome xenograft rejection.